上海遥健医疗科技

Yaojian Medical is a Shanghai-based medical technology company specializing in the development of innovative transcatheter structural heart disease therapies. Founded in 2021 by industry veterans, the company focuses on next-generation transcatheter aortic valve replacement (TAVR) and mitral valve repair systems. Their technology aims to improve clinical outcomes and procedural ease for patients suffering from valvular heart diseases. Yaojian Medical is headquartered in the Zhangjiang Hi-Tech Park and has established advanced R&D and manufacturing facilities. The company has successfully raised significant capital from leading investors, including Sequoia China and GL Ventures, to advance its clinical pipeline. Their products are designed to address complex anatomical challenges in the cardiovascular field.